Conmed (CNMD) Tops Q4 EPS by 1c, Offers FY Guidance

Conmed (NASDAQ: CNMD) reported Q4 EPS of $0.73, $0.01 better than the analyst estimate of $0.72. Revenue for the quarter came in at $242.4 million versus the consensus estimate of $228.8 million.

GUIDANCE:

Conmed sees FY2019 EPS of $2.42-$2.47, versus the consensus of $2.42.

• The Company expects full-year 2019 constant-currency sales growth in the range of 5.0% to 6.0%.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Yeti outlines growth targets and financial framework through 2030
• Could Affirm be a $200 stock?